SCHEMBL2625552

SCHEMBL2625552

CC(C)Nc1ncc[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25760621 0.83 FDPS (0.50)
SCHEMBL22827208 0.83
SCHEMBL9537489 0.78 FDPS (0.42)
SCHEMBL2638056 0.77 FDPS (0.53)
SCHEMBL11103701 0.77 FDPS (0.53)
SCHEMBL17099961 0.77 FDPS (0.45)
SCHEMBL2638054 0.77 FDPS (0.53)
SCHEMBL3786576 0.75 GAA (0.46)
SCHEMBL1845858 0.75 GAA (0.46)
SCHEMBL25794780 0.75 FDPS (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023196975-A1 COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE SHY THERAPEUTICS, LLC (US) 2023-10-12 WO disclosed
US-11639353-B2 Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2023-05-02 US disclosed
US-11639353-B2 Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2023-05-02 US disclosed
US-11207312-B2 Metallo-beta-lactamase inhibitors and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2021-12-28 US disclosed
US-20210246136-A1 CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-08-12 US disclosed
US-20210188847-A1 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-06-24 US disclosed
US-11028071-B2 Indazole derivatives as alpha v integrin antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2021-06-08 US disclosed
US-11014922-B2 Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2021-05-25 US disclosed
US-10968219-B2 3-substituted propionic acids as αV integrin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2021-04-06 US disclosed
US-20210087184-A1 AMINO-BENZOISOTHIAZOLE AND AMINO-BENZOISOTHIADIAZOLE AMIDE COMPOUNDS ALCON INC. (CH) 2021-03-25 US disclosed
US-8507723-B2 Polycationic compounds and uses thereof POLYMEDIX, INC. (US) 2013-08-13 US disclosed
US-20120322878-A1 Polycationic Compounds And Uses Thereof POLYMEDIX, INC. (US) 2012-12-20 US disclosed
US-8329906-B2 Guanidinyl-substituted hydroxy-6-phenylphenanthridines NYCOMED GMBH (DE) 2012-12-11 US disclosed
US-8163763-B2 Pyrimidine compounds, compositions and methods of use GENENTECH, INC. (US) 2012-04-24 US disclosed
US-7745662-B2 Polycationic compounds and uses thereof POLYMEDIX, INC. (US) 2010-06-29 US disclosed
US-20100035913-A1 Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (PDE) 4 inhibitors NYCOMED GMBH (DE) 2010-02-11 US disclosed
US-20090239811-A1 POLYCATIONIC COMPOUNDS AND USES THEREOF POLYMEDIX, INC. (US) 2009-09-24 US disclosed
US-7585872-B2 Guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (PDE) 4 inhibitors NYCOMED GMBH (DE) 2009-09-08 US disclosed
US-7553876-B2 Polycationic compounds and uses thereof POLYMEDIX, INC. (US) 2009-06-30 US disclosed
US-20070167482-A1 Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors ALTANA PHARMA AG (DE) 2007-07-19 US disclosed